UnknownNot applicableNCT03481868

EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors

Studying Chronic myeloid leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Hospital, Clermont-Ferrand
Principal Investigator
Marc BERGER
University Hospital, Clermont-Ferrand
Intervention
Collection of blood and bone marrow(biological)
Enrollment
160 enrolled
Eligibility
18 years · All sexes
Timeline
2018 – 2026

Study locations (16)

Collaborators

Institut Paoli-Calmettes · CHRU Lille, hematology department · CH Annecy Genevois · Institut Bergonié Bordeaux, hematology department · Central Hospital, Nancy, France · CHU Saint-Etienne, hematology department · Institut Universitaire du Cancer de Toulouse · CHU Caen, hematology department · CHU Nice, hematology department · Hospices Civils de Lyon · AP-HP, hematology department · AP-HP Hôpital Henri-Mondor, hematology department · Versailles Hospital · Centre Leon Berard · University Hospital, Grenoble

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03481868 on ClinicalTrials.gov

Other trials for Chronic myeloid leukemia

Additional recruiting or active studies for the same condition.

See all trials for Chronic myeloid leukemia →

← Back to all trials